← Back to Screener
MaxCyte, Inc. Common Stock (MXCT)
Price$0.82
Favorite Metrics
Price vs S&P 500 (26W)-54.27%
Price vs S&P 500 (4W)9.80%
Market Capitalization$87.12M
All Metrics
Book Value / Share (Quarterly)$1.61
P/TBV (Annual)0.97x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-9.30%
Cash Flow / Share (Quarterly)$-0.34
Price vs S&P 500 (YTD)-48.11%
Gross Margin (TTM)81.16%
Net Profit Margin (TTM)-135.14%
EPS (TTM)$-0.42
10-Day Avg Trading Volume0.87M
EPS Excl Extra (TTM)$-0.42
Revenue Growth (5Y)4.76%
EPS (Annual)$-0.42
ROI (Annual)-26.02%
Gross Margin (Annual)81.16%
Net Profit Margin (5Y Avg)-88.57%
Cash / Share (Quarterly)$0.96
Revenue Growth QoQ (YoY)-16.02%
ROA (Last FY)-22.04%
Revenue Growth TTM (YoY)-14.50%
EBITD / Share (TTM)$-0.45
ROE (5Y Avg)-15.76%
Operating Margin (TTM)-157.14%
Cash Flow / Share (Annual)$-0.34
P/B Ratio0.51x
P/B Ratio (Quarterly)0.96x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.03x
Net Interest Coverage (TTM)-20.44x
ROA (TTM)-20.62%
EPS Incl Extra (Annual)$-0.42
Current Ratio (Annual)8.30x
Quick Ratio (Quarterly)7.47x
3-Month Avg Trading Volume1.15M
52-Week Price Return-67.49%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.60
P/S Ratio (Annual)2.64x
Asset Turnover (Annual)0.16x
52-Week High$2.96
Operating Margin (5Y Avg)-104.43%
EPS Excl Extra (Annual)$-0.42
CapEx CAGR (5Y)-3.10%
Tangible BV CAGR (5Y)66.92%
26-Week Price Return-50.28%
Quick Ratio (Annual)7.47x
13-Week Price Return-37.85%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.30x
Enterprise Value$67.059
Revenue / Share Growth (5Y)-3.81%
Asset Turnover (TTM)0.15x
Book Value / Share Growth (5Y)45.14%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.76x
Pretax Margin (Annual)-135.14%
Cash / Share (Annual)$0.96
3-Month Return Std Dev65.61%
Gross Margin (5Y Avg)85.81%
Net Income / Employee (TTM)$-0
ROE (Last FY)-26.02%
EPS Basic Excl Extra (Annual)$-0.42
Receivables Turnover (TTM)8.07x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.42
Receivables Turnover (Annual)8.07x
ROI (TTM)-24.06%
P/S Ratio (TTM)2.64x
Pretax Margin (5Y Avg)-88.57%
Revenue / Share (Annual)$0.31
Tangible BV / Share (Annual)$1.60
Price vs S&P 500 (52W)-97.32%
Year-to-Date Return-45.47%
5-Day Price Return11.21%
EPS Normalized (Annual)$-0.42
ROA (5Y Avg)-13.65%
Net Profit Margin (Annual)-135.14%
Month-to-Date Return20.23%
Cash Flow / Share (TTM)$-0.33
EBITD / Share (Annual)$-0.45
Operating Margin (Annual)-157.14%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-15.76%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.42
P/TBV (Quarterly)0.97x
P/B Ratio (Annual)0.96x
Inventory Turnover (TTM)0.76x
Pretax Margin (TTM)-135.14%
Book Value / Share (Annual)$1.61
Price vs S&P 500 (13W)-38.54%
Beta1.52x
Revenue / Share (TTM)$0.31
ROE (TTM)-24.06%
52-Week Low$0.64
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.15
4.15
4.15
4.15
Industry Peers — R&D — Physical Sciences(9)
| Symbol | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|
MXCTMaxCyte, Inc. Common Stock | — | -24.06% | 4.76% | — | $0.82 |
IQVIQVIA Holdings Inc. | 22.22x | 22.28% | 7.50% | — | $171.95 |
INCYIncyte Genomics Inc | 14.67x | 29.15% | 14.03% | — | $95.32 |
MEDPMedpace Holdings, Inc. Common Stock | 32.83x | 118.82% | 22.27% | — | $515.65 |
CRLCharles River Laboratories International, Inc. | — | -4.40% | 6.55% | — | $176.94 |
ABSIAbsci Corporation Common Stock | — | -59.68% | -10.14% | — | $3.23 |
NRCNational Research Corporation Common Stock (Delaware) | 34.98x | 58.51% | 0.61% | 3.59% | $17.62 |
OABIOmniAb, Inc. Common Stock | — | -23.99% | -4.31% | — | $1.56 |
NOTVInotiv, Inc. Common Stock | — | -50.77% | 53.35% | — | $0.30 |
ISPCiSpecimen Inc. Common Stock | — | -496.37% | -25.09% | — | $0.12 |
About
MaxCyte Inc is a commercial cell engineering company that develops and commercializes technologies for the discovery and development of next-generation cell therapeutics. The company's proprietary Flow Electroporation platform enables the efficient engineering of diverse cell types for therapeutic and research applications. MaxCyte generates revenue from the sale and licensing of its instruments and related single-use disposable processing assemblies.